Hiroaki Ozasa

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Advanced Non Small Cell Lung Cancer

Tyrosine Kinase

Epidermal Growth Factor Receptor

Top Venues

Science translational medicine

ERJ open research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Kazutoshi Isobe, Yasuhiko Nakamura, Susumu Sakamoto, Keisuke Tomii, Takayuki Takimoto, Yasunari Miyazaki, Masaru Matsumoto, Keishi Sugino, Kazuya Ichikado, Shuhei Moriguchi, Kakuhiro Yamaguchi, Tomohisa Baba, Hiroaki Ozasa, Fumiyasu Igata, Kazuki Anabuki, Sakae Homma, Hiroshi Date, Takafumi Suda, Kazuma Kishi
Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia. ERJ open research 10 (2) (2024)
Kazutoshi Isobe, Yasuhiko Nakamura, Susumu Sakamoto, Keisuke Tomii, Takayuki Takimoto, Yasunari Miyazaki, Masaru Matsumoto, Keishi Sugino, Kazuya Ichikado, Shuhei Moriguchi, Kakuhiro Yamaguchi, Tomohisa Baba, Hiroaki Ozasa, Fumiyasu Igata, Kazuki Anabuki, Sakae Homma, Hiroshi Date, Takafumi Suda, Kazuma Kishi
Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia. ERJ open research 10 (2) (2024)
Tatsuya Ogimoto, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Yamamoto Funazo, Masatoshi Yamazoe, Kentaro Hashimoto, Hiroshi Yoshida, Kazutaka Hosoya, Hitomi Ajimizu, Takashi Nomizo, Hironori Yoshida, Masatsugu Hamaji, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai
Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer. Molecular cancer therapeutics (2023)
Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna, Young Hak Kim, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Tomoko Hirano, Fumihiko Matsuda, Toyohiro Hirai, Kazuto Nishio, Takuro Sakagami, Masanori Fukushima, Yoichi Nakanishi, Tasuku Honjo, Isamu Okamoto
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer. Science translational medicine 14 (675) (2022)
Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna, Young Hak Kim, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Tomoko Hirano, Fumihiko Matsuda, Toyohiro Hirai, Kazuto Nishio, Takuro Sakagami, Masanori Fukushima, Yoichi Nakanishi, Tasuku Honjo, Isamu Okamoto
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer. Science translational medicine 14 (675) (2022)
Kentaro Tanaka, Kenji Chamoto, Sho Saeki, Ryusuke Hatae, Yuki Ikematsu, Kazuko Sakai, Nobuhisa Ando, Kazuhiro Sonomura, Shinsuke Kojima, Masanori Taketsuna, Young Hak Kim, Hironori Yoshida, Hiroaki Ozasa, Yuichi Sakamori, Tomoko Hirano, Fumihiko Matsuda, Toyohiro Hirai, Kazuto Nishio, Takuro Sakagami, Masanori Fukushima, Yoichi Nakanishi, Tasuku Honjo, Isamu Okamoto
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer. Science translational medicine 14 (675) (2022)
Masatoshi Yamazoe, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Hiroshi Yoshida, Kentaro Hashimoto, Kazutaka Hosoya, Tatsuya Ogimoto, Hitomi Ajimizu, Hironori Yoshida, Ryo Itotani, Yuichi Sakamori, Kiyomitsu Kuninaga, Wataru Aoki, Toyohiro Hirai
Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer. Cancer science (2022)